<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320528</url>
  </required_header>
  <id_info>
    <org_study_id>9867</org_study_id>
    <secondary_id>B4Z-IT-LYDS</secondary_id>
    <nct_id>NCT00320528</nct_id>
  </id_info>
  <brief_title>Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder With or Without Comorbid Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the effectiveness of atomoxetine on psychosocial functioning and
      emotional well being of children and adolescents with ADHD and to evaluate whether and in
      what measure the presence of comorbid conditions (internalizing and externalizing disorders)
      influences atomoxetine's ability to improve the quality of life of ADHD subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Child Health and Illness Profile - Child Edition (CHIP-CE), Achievement Domain</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in the Attention-Deficit/Hyperactivity Disorder (ADHD) Subscales of 18-Item Swanson, Nolan and Pelham Rating Scale (SNAP-IV)</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S)</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in CHIP-CE Satisfaction, Comfort, Resilience and Risk Avoidance Domains</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Pediatric Anxiety Rating Scale (PARS)</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Children's Depression Rating Scale-Revised (CDRS-R)</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in SNAP-IV Oppositional Scale</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Adolescent Symptom Inventory-4: Parent Checklist (ASI-4)</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Child Symptom Inventory-4: Parent Checklist (CSI-4)</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Conners' Teacher Rating Scale-Revised: Short Form (CTRS-R:S)</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">269</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>Pure ADHD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADHD+Internalizing Disorders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADHD+Externalizing Disorders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atomoxetine</intervention_name>
    <description>0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
    <arm_group_label>Pure ADHD</arm_group_label>
    <arm_group_label>ADHD+Internalizing Disorders</arm_group_label>
    <arm_group_label>ADHD+Externalizing Disorders</arm_group_label>
    <other_name>LY139603</other_name>
    <other_name>Strattera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child or adolescent patients, male or female outpatients, who are at least 6 years of
             age, but must not yet have reached their 16th birthday prior to Visit 1, when informed
             consent is obtained

          -  Patients must meet Diagnostic and Statistical Manual of Mental Disorders Fourth
             Edition (DSM-IV) diagnostic criteria for ADHD (any subtype) and score at least 1.5
             standard deviations above the age norm for their diagnostic subtype using published
             norms for the Swanson, Nolan and Pelham Questionnaire: Attention-Deficit/Hyperactivity
             Disorder Subscale (SNAP-IV ADHD Subscale) score at both Visit 1 and 2

          -  Laboratory results, including serum chemistries, hematology, and urinalysis, must show
             no clinically significant abnormalities (clinically significant is defined as
             laboratory values requiring acute medical intervention, indicating a serious medical
             illness, or requiring further medical evaluation in the judgment of the investigator)

          -  An electrocardiogram (ECG) must be performed to exclude cardiac diseases at the
             baseline/screening visit and the results must be reviewed by the investigator at Visit
             2 prior to dispensing of study material

          -  Patients and parents have been judged by the investigator to be reliable to keep
             appointments for clinic visits and all tests, including venipuncture, and examinations
             required by the protocol.

        Exclusion Criteria:

          -  Patients who have a documented history of Bipolar I or II disorder, any history of
             psychosis or pervasive development disorder

          -  Patients with a history of any seizure disorder (other than febrile seizures) or
             patients who have taken (or are currently taking) anticonvulsants for seizure control
             are not eligible to participate

          -  Patients at serious suicidal risk as assessed by the investigator

          -  Patients with significant cardiovascular disease or other conditions that could be
             aggravated by an increased heart rate or increased blood pressure

          -  Patients who have any medical condition that would increase sympathetic nervous system
             activity markedly (for example, catecholamine-secreting neural tumor), or who are
             taking a medication on a daily basis (for example, albuterol, inhalation aerosols,
             pseudoephedrine), that has sympathomimetic activity. Such medications can be taken on
             an as-needed basis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Acireale</city>
        <zip>95024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bosisio Parini</city>
        <zip>23842</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Catania</city>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coppito</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milano</city>
        <zip>20129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ostuni</city>
        <zip>72017</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palermo</city>
        <zip>90145</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Perugia</city>
        <zip>06100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rho</city>
        <zip>20017</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Savigliano</city>
        <zip>12038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Trieste</city>
        <zip>34137</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Troina</city>
        <zip>94018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Viterbo</city>
        <zip>01100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2006</study_first_submitted>
  <study_first_submitted_qc>May 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <results_first_submitted>September 30, 2009</results_first_submitted>
  <results_first_submitted_qc>December 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2010</results_first_posted>
  <last_update_submitted>December 2, 2009</last_update_submitted>
  <last_update_submitted_qc>December 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study Period I was a 3-day screening period. Study Period II was 12 weeks long. Study Period III was an optional additional 12 week open-label extension. Results are presented for Period II (patients who received at least one dose of study drug).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pure ADHD</title>
          <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
        </group>
        <group group_id="P2">
          <title>ADHD+Internalizing Disorders</title>
          <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
        </group>
        <group group_id="P3">
          <title>ADHD+Externalizing Disorders</title>
          <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study Period II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent/Caregiver Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Exclusion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Period III</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="106"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent/Caregiver Decision</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Atomoxetine Commercially Available</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="90"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pure ADHD</title>
          <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
        </group>
        <group group_id="B2">
          <title>ADHD+Internalizing Disorders</title>
          <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
        </group>
        <group group_id="B3">
          <title>ADHD+Externalizing Disorders</title>
          <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="128"/>
            <count group_id="B4" value="263"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.12" spread="2.51"/>
                    <measurement group_id="B2" value="10.42" spread="2.41"/>
                    <measurement group_id="B3" value="10.00" spread="2.57"/>
                    <measurement group_id="B4" value="10.11" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Child Health and Illness Profile - Child Edition (CHIP-CE) - Achievement Domain</title>
          <description>Parent-rated assessment of a child’s health status and level of functioning. It consists of 76 items. The majority of items assess frequency of activities or feelings using a five-point response format (for example, ‘how good is your child at making friends?’ 1=never, 5=always). Standard scores (t-value) were established, with all domains and subdomains having a mean score of 50 and standard deviation of 10. Standard scores are expressed in standard deviation units. Achievement Domain Range = -3.1 to 67.7. Higher scores mean greater health or level of functioning in achievement.</description>
          <units>T-Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Achievement Domain (N=96, N=33, N=121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.27" spread="7.89"/>
                    <measurement group_id="B2" value="27.72" spread="7.73"/>
                    <measurement group_id="B3" value="25.83" spread="7.60"/>
                    <measurement group_id="B4" value="27.40" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction Domain (N=96, N=24, N=122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.26" spread="13.89"/>
                    <measurement group_id="B2" value="30.11" spread="14.83"/>
                    <measurement group_id="B3" value="31.69" spread="14.78"/>
                    <measurement group_id="B4" value="34.34" spread="14.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comfort Domain (N=96, N=35, N=122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.31" spread="9.40"/>
                    <measurement group_id="B2" value="46.76" spread="12.28"/>
                    <measurement group_id="B3" value="44.74" spread="9.38"/>
                    <measurement group_id="B4" value="47.51" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resilience Domain (N=96, N=34, N=123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.34" spread="10.15"/>
                    <measurement group_id="B2" value="34.96" spread="10.89"/>
                    <measurement group_id="B3" value="31.40" spread="11.85"/>
                    <measurement group_id="B4" value="34.89" spread="11.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Risk Avoidance (N=96, N=33, N=121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.03" spread="9.7"/>
                    <measurement group_id="B2" value="30.48" spread="12.29"/>
                    <measurement group_id="B3" value="22.85" spread="12.00"/>
                    <measurement group_id="B4" value="27.38" spread="12.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Children's Depression Rating Scale-Revised (CDRS-R)</title>
          <description>Measures presence and severity of depression. Consists of 17 items scored on a 1-5 or 1-7 scale. A rating of 1 indicates normal, thus the minimum score is 17. The maximum score is 113. In general, scores below 20 indicate an absence of depression; scores of 20 or 30 indicate borderline depression; scores of 40 to 60 indicate moderate depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.93" spread="12.26"/>
                    <measurement group_id="B2" value="43.76" spread="13.48"/>
                    <measurement group_id="B3" value="43.06" spread="13.69"/>
                    <measurement group_id="B4" value="41.26" spread="13.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S)</title>
          <description>Measures severity of the patient's overall severity of ADHD symptoms (1=normal, not at all ill; 7=among the most extremely ill patients).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.64" spread="0.79"/>
                    <measurement group_id="B2" value="4.97" spread="0.79"/>
                    <measurement group_id="B3" value="4.98" spread="0.78"/>
                    <measurement group_id="B4" value="4.85" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conners' Teacher Rating Scale-Revised:Short Form (CTRS-R:S)</title>
          <description>A 28-item rating scale (0 [not at all/never] to 3 [very much true/very often]) completed by the teacher to assess problem behaviors related to ADHD. Subscale total scores range from 0 to 15 for Oppositional and Cognitive Problems, 0 to 21 for Hyperactivity, and 0 to 36 for ADHD Index.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Oppositional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.97" spread="4.93"/>
                    <measurement group_id="B2" value="4.97" spread="4.66"/>
                    <measurement group_id="B3" value="8.62" spread="4.83"/>
                    <measurement group_id="B4" value="7.10" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.86" spread="3.73"/>
                    <measurement group_id="B2" value="7.68" spread="3.80"/>
                    <measurement group_id="B3" value="7.96" spread="3.61"/>
                    <measurement group_id="B4" value="7.88" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.38" spread="6.09"/>
                    <measurement group_id="B2" value="12.03" spread="5.21"/>
                    <measurement group_id="B3" value="14.67" spread="5.15"/>
                    <measurement group_id="B4" value="13.05" spread="5.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADHD Index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.14" spread="6.86"/>
                    <measurement group_id="B2" value="22.94" spread="6.01"/>
                    <measurement group_id="B3" value="25.18" spread="6.07"/>
                    <measurement group_id="B4" value="23.70" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pediatric Anxiety Rating Scale (PARS)</title>
          <description>The Pediatric Anxiety Rating Scale (PARS) is used to rate the severity of anxiety in children and adolescents, ages 6 to 17 years. The total score for the PARS is derived by summing 5 of the 7 severity/impairment/interference items (2,3,5,6,7). The total score ranges from 0 (none) to 25 (extreme severity). Items 1 (overall number of anxiety symptoms) and 4 (overall severity of physical symptoms) are not included in the total score calculation.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.50" spread="2.67"/>
                    <measurement group_id="B2" value="7.50" spread="5.68"/>
                    <measurement group_id="B3" value="4.67" spread="5.12"/>
                    <measurement group_id="B4" value="4.28" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swanson, Nolan, and Pelham Rating Scale Revised (SNAP-IV)</title>
          <description>The SNAP-IV is a 26-item scale that includes 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD and 1 item for each of the 8 symptoms contained in the DSM-IV diagnosis of ODD. Each item is score on 0 to 3 scale (0 = “Not at All”, 1 = “Just a Little”, 2 = “Pretty Much”, 3 = “Very Much”). The SNAP-IV yields scores in three domains: Inattention (items 1-9: subscore range=0-27), Hyperactivity/impulsivity (items 10-18: subscale range=0-27), and Oppositional (items 19-26: subscale range=0-24). Combined type (inattention + hyperactivity/impulsivity) scores range from 0-54.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Inattention Subscale (N=97, N=38, N=127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.28" spread="4.19"/>
                    <measurement group_id="B2" value="21.03" spread="3.72"/>
                    <measurement group_id="B3" value="21.87" spread="3.48"/>
                    <measurement group_id="B4" value="21.16" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperactivity/Impulsivity Subscale (N=97, N=38, N=</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.21" spread="6.10"/>
                    <measurement group_id="B2" value="19.66" spread="5.54"/>
                    <measurement group_id="B3" value="21.04" spread="3.48"/>
                    <measurement group_id="B4" value="19.42" spread="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combined Type Subscale (N=97, N=38, N=127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.48" spread="7.78"/>
                    <measurement group_id="B2" value="40.68" spread="7.87"/>
                    <measurement group_id="B3" value="42.91" spread="5.51"/>
                    <measurement group_id="B4" value="40.58" spread="7.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oppositional Subscale (N=97, N=38, N=127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.15" spread="4.54"/>
                    <measurement group_id="B2" value="12.32" spread="4.67"/>
                    <measurement group_id="B3" value="17.99" spread="3.57"/>
                    <measurement group_id="B4" value="14.27" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 12 Week Endpoint in Child Health and Illness Profile - Child Edition (CHIP-CE), Achievement Domain</title>
        <description>Parent-rated assessment of a child’s health status and level of functioning. It consists of 76 items. The majority of items assess frequency of activities or feelings using a five-point response format (for example, ‘how good is your child at making friends?’ 1=never, 5=always). Standard scores (t-value) were established, with all domains and subdomains having a mean score of 50 and standard deviation of 10. Standard scores are expressed in standard deviation units. Achievement Domain Range = -3.1 to 67.7. Higher scores mean greater health or level of functioning in achievement.</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pure ADHD</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O2">
            <title>ADHD+Internalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O3">
            <title>ADHD+Externalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Child Health and Illness Profile - Child Edition (CHIP-CE), Achievement Domain</title>
          <description>Parent-rated assessment of a child’s health status and level of functioning. It consists of 76 items. The majority of items assess frequency of activities or feelings using a five-point response format (for example, ‘how good is your child at making friends?’ 1=never, 5=always). Standard scores (t-value) were established, with all domains and subdomains having a mean score of 50 and standard deviation of 10. Standard scores are expressed in standard deviation units. Achievement Domain Range = -3.1 to 67.7. Higher scores mean greater health or level of functioning in achievement.</description>
          <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
          <units>T-Score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" lower_limit="0.93" upper_limit="4.37"/>
                    <measurement group_id="O2" value="0.51" lower_limit="-1.38" upper_limit="2.39"/>
                    <measurement group_id="O3" value="3.89" lower_limit="2.22" upper_limit="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in the Attention-Deficit/Hyperactivity Disorder (ADHD) Subscales of 18-Item Swanson, Nolan and Pelham Rating Scale (SNAP-IV)</title>
        <description>Items from the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for ADHD are included for the two subsets of symptoms: inattention (items #1-#9: total score=0-27) and hyperactivity/impulsivity (items #11-#19: total score=0-27). The SNAP-IV is based on a 0 (not at all) to 3 (very much) rating scale. Total combined type (inattention plus hyperactivity/impulsivity) subscale scores range from 0 to 54.</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pure ADHD</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O2">
            <title>ADHD+Internalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O3">
            <title>ADHD+Externalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in the Attention-Deficit/Hyperactivity Disorder (ADHD) Subscales of 18-Item Swanson, Nolan and Pelham Rating Scale (SNAP-IV)</title>
          <description>Items from the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for ADHD are included for the two subsets of symptoms: inattention (items #1-#9: total score=0-27) and hyperactivity/impulsivity (items #11-#19: total score=0-27). The SNAP-IV is based on a 0 (not at all) to 3 (very much) rating scale. Total combined type (inattention plus hyperactivity/impulsivity) subscale scores range from 0 to 54.</description>
          <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inattention Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.88" lower_limit="-6.97" upper_limit="-4.78"/>
                    <measurement group_id="O2" value="-5.52" lower_limit="-7.34" upper_limit="-3.69"/>
                    <measurement group_id="O3" value="-7.58" lower_limit="-8.69" upper_limit="-6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperactivity/Impulsivity Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.19" lower_limit="-7.25" upper_limit="-5.13"/>
                    <measurement group_id="O2" value="-5.67" lower_limit="-7.41" upper_limit="-3.92"/>
                    <measurement group_id="O3" value="-8.08" lower_limit="-9.09" upper_limit="-7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combined Type (ADHD) Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" lower_limit="-13.9" upper_limit="-10.3"/>
                    <measurement group_id="O2" value="-11.2" lower_limit="-14.4" upper_limit="-7.92"/>
                    <measurement group_id="O3" value="-15.7" lower_limit="-17.6" upper_limit="-13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S)</title>
        <description>Measures severity of the patient's overall severity of ADHD symptoms (1=normal, not at all ill; 7=among the most extremely ill patients).</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pure ADHD</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O2">
            <title>ADHD+Internalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O3">
            <title>ADHD+Externalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S)</title>
          <description>Measures severity of the patient's overall severity of ADHD symptoms (1=normal, not at all ill; 7=among the most extremely ill patients).</description>
          <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" lower_limit="-1.46" upper_limit="-0.99"/>
                    <measurement group_id="O2" value="-1.63" lower_limit="-1.99" upper_limit="-1.26"/>
                    <measurement group_id="O3" value="-1.42" lower_limit="-1.63" upper_limit="-1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in CHIP-CE Satisfaction, Comfort, Resilience and Risk Avoidance Domains</title>
        <description>Parent-rated assessment of a child’s health status and level of functioning. It consists of 76 items. The majority of items assess frequency of activities or feelings using a five-point response format (for example, ‘how good is your child at making friends?’ 1=never, 5=always). Standard scores (t-value) were established, with all domains having a mean score of 50 and standard deviation of 10. Satisfaction range=-25.7 to 66.3; Comfort=-28.6 to 67.2; Resilience=-36.3 to 71.8; Risk Avoidance=-23.5 to 62.5. Higher scores mean greater health or level of functioning in that domain.</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pure ADHD</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O2">
            <title>ADHD+Internalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O3">
            <title>ADHD+Externalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in CHIP-CE Satisfaction, Comfort, Resilience and Risk Avoidance Domains</title>
          <description>Parent-rated assessment of a child’s health status and level of functioning. It consists of 76 items. The majority of items assess frequency of activities or feelings using a five-point response format (for example, ‘how good is your child at making friends?’ 1=never, 5=always). Standard scores (t-value) were established, with all domains having a mean score of 50 and standard deviation of 10. Satisfaction range=-25.7 to 66.3; Comfort=-28.6 to 67.2; Resilience=-36.3 to 71.8; Risk Avoidance=-23.5 to 62.5. Higher scores mean greater health or level of functioning in that domain.</description>
          <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
          <units>T-Score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Satisfaction Domain (N=88, N=31, N=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" lower_limit="-0.06" upper_limit="4.34"/>
                    <measurement group_id="O2" value="0.81" lower_limit="-3.33" upper_limit="4.95"/>
                    <measurement group_id="O3" value="3.78" lower_limit="1.18" upper_limit="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comfort Domain (N=86, N=28, N=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="-0.88" upper_limit="2.90"/>
                    <measurement group_id="O2" value="5.72" lower_limit="1.24" upper_limit="10.19"/>
                    <measurement group_id="O3" value="4.94" lower_limit="3.14" upper_limit="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resilience Domain (N=87, N=30, N=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit="-0.85" upper_limit="3.27"/>
                    <measurement group_id="O2" value="2.18" lower_limit="-1.31" upper_limit="5.67"/>
                    <measurement group_id="O3" value="3.07" lower_limit="1.10" upper_limit="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Risk Avoidance Domain (N=82, N=28, N=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" lower_limit="2.93" upper_limit="6.51"/>
                    <measurement group_id="O2" value="5.70" lower_limit="1.96" upper_limit="9.45"/>
                    <measurement group_id="O3" value="9.88" lower_limit="7.88" upper_limit="11.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Pediatric Anxiety Rating Scale (PARS)</title>
        <description>The Pediatric Anxiety Rating Scale (PARS) is used to rate the severity of anxiety in children and adolescents, ages 6 to 17 years. The total score for the PARS is derived by summing 5 of the 7 severity/impairment/interference items (2,3,5,6,7). The total score ranges from 0 (none) to 25 (extreme severity). Items 1 (overall number of anxiety symptoms) and 4 (overall severity of physical symptoms) are not included in the total score calculation.</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pure ADHD</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O2">
            <title>ADHD+Internalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O3">
            <title>ADHD+Externalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Pediatric Anxiety Rating Scale (PARS)</title>
          <description>The Pediatric Anxiety Rating Scale (PARS) is used to rate the severity of anxiety in children and adolescents, ages 6 to 17 years. The total score for the PARS is derived by summing 5 of the 7 severity/impairment/interference items (2,3,5,6,7). The total score ranges from 0 (none) to 25 (extreme severity). Items 1 (overall number of anxiety symptoms) and 4 (overall severity of physical symptoms) are not included in the total score calculation.</description>
          <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" lower_limit="-0.70" upper_limit="0.34"/>
                    <measurement group_id="O2" value="-1.88" lower_limit="-3.40" upper_limit="-0.36"/>
                    <measurement group_id="O3" value="-1.18" lower_limit="-1.90" upper_limit="-0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Children's Depression Rating Scale-Revised (CDRS-R)</title>
        <description>Measures presence and severity of depression. Consists of 17 items scored on a 1-5 or 1-7 scale. A rating of 1 indicates normal, thus the minimum score is 17. The maximum score is 113. In general, scores below 20 indicate an absence of depression; scores of 20 or 30 indicate borderline depression; scores of 40 to 60 indicate moderate depression.</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pure ADHD</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O2">
            <title>ADHD+Internalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O3">
            <title>ADHD+Externalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Children's Depression Rating Scale-Revised (CDRS-R)</title>
          <description>Measures presence and severity of depression. Consists of 17 items scored on a 1-5 or 1-7 scale. A rating of 1 indicates normal, thus the minimum score is 17. The maximum score is 113. In general, scores below 20 indicate an absence of depression; scores of 20 or 30 indicate borderline depression; scores of 40 to 60 indicate moderate depression.</description>
          <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.60" lower_limit="-3.54" upper_limit="0.34"/>
                    <measurement group_id="O2" value="-2.56" lower_limit="-6.38" upper_limit="1.25"/>
                    <measurement group_id="O3" value="-3.13" lower_limit="-4.64" upper_limit="-1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in SNAP-IV Oppositional Scale</title>
        <description>Items are included from the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for Oppositional Defiant Disorder. The SNAP-IV is based on a 0 (not at all) to 3 (very much) rating scale. Total subscale scores range from 0 to 24.</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pure ADHD</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O2">
            <title>ADHD+Internalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O3">
            <title>ADHD+Externalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in SNAP-IV Oppositional Scale</title>
          <description>Items are included from the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for Oppositional Defiant Disorder. The SNAP-IV is based on a 0 (not at all) to 3 (very much) rating scale. Total subscale scores range from 0 to 24.</description>
          <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" lower_limit="-2.86" upper_limit="-1.16"/>
                    <measurement group_id="O2" value="-2.12" lower_limit="-3.95" upper_limit="-0.29"/>
                    <measurement group_id="O3" value="-5.54" lower_limit="-6.43" upper_limit="-4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Adolescent Symptom Inventory-4: Parent Checklist (ASI-4)</title>
        <description>Parent-completed ASI-4 contains 120 items on 18 emotional and behavioral disorders in adolescents (12-18 years old). Item score range:0 (no symptoms) to 3 (maximum impairment). Categories: A=ADHD (0-54); B=Conduct (0-60); C=Oppositional Defiant (0-24); D=Generalized Anxiety (0-18); E=Specific Phobia/Panic Attack/Obsessions/Compulsions/Somatization (0-30); F=Social Phobia (0-6); G=Separation Anxiety (0-24); H=Schizoid Personality (0-9); I=Schizophrenia (0-6); J=Enuresis (0-18); K=Major Depressive (0-42); L=Bipolar (0-27); M=Anorexia (0-12); N=Bulimia (0-12); O=Substance Abuse (0-18).</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <population>Number of adolescent patients with baseline and at least one nonmissing post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pure ADHD</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O2">
            <title>ADHD+Internalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O3">
            <title>ADHD+Externalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Adolescent Symptom Inventory-4: Parent Checklist (ASI-4)</title>
          <description>Parent-completed ASI-4 contains 120 items on 18 emotional and behavioral disorders in adolescents (12-18 years old). Item score range:0 (no symptoms) to 3 (maximum impairment). Categories: A=ADHD (0-54); B=Conduct (0-60); C=Oppositional Defiant (0-24); D=Generalized Anxiety (0-18); E=Specific Phobia/Panic Attack/Obsessions/Compulsions/Somatization (0-30); F=Social Phobia (0-6); G=Separation Anxiety (0-24); H=Schizoid Personality (0-9); I=Schizophrenia (0-6); J=Enuresis (0-18); K=Major Depressive (0-42); L=Bipolar (0-27); M=Anorexia (0-12); N=Bulimia (0-12); O=Substance Abuse (0-18).</description>
          <population>Number of adolescent patients with baseline and at least one nonmissing post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Category A - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.73" spread="11.42"/>
                    <measurement group_id="O2" value="38.33" spread="10.32"/>
                    <measurement group_id="O3" value="38.13" spread="8.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category A - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="9.88"/>
                    <measurement group_id="O2" value="-10.4" spread="11.55"/>
                    <measurement group_id="O3" value="-11.6" spread="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category B - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" spread="4.25"/>
                    <measurement group_id="O2" value="6.00" spread="5.62"/>
                    <measurement group_id="O3" value="10.80" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category B - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="2.92"/>
                    <measurement group_id="O2" value="-0.60" spread="5.83"/>
                    <measurement group_id="O3" value="-5.57" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category C- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.92" spread="4.77"/>
                    <measurement group_id="O2" value="10.50" spread="3.72"/>
                    <measurement group_id="O3" value="15.60" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category C - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="3.85"/>
                    <measurement group_id="O2" value="-1.40" spread="6.15"/>
                    <measurement group_id="O3" value="-5.47" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category D- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" spread="3.14"/>
                    <measurement group_id="O2" value="9.20" spread="3.58"/>
                    <measurement group_id="O3" value="8.37" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category D - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="3.09"/>
                    <measurement group_id="O2" value="-1.70" spread="3.65"/>
                    <measurement group_id="O3" value="-2.97" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category E- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="4.00"/>
                    <measurement group_id="O2" value="7.60" spread="7.85"/>
                    <measurement group_id="O3" value="3.63" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category E - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="4.01"/>
                    <measurement group_id="O2" value="-4.50" spread="8.72"/>
                    <measurement group_id="O3" value="-1.30" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category F- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="1.27"/>
                    <measurement group_id="O2" value="2.60" spread="1.43"/>
                    <measurement group_id="O3" value="1.20" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category F - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.81"/>
                    <measurement group_id="O2" value="-1.40" spread="1.43"/>
                    <measurement group_id="O3" value="-0.53" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category G- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" spread="3.50"/>
                    <measurement group_id="O2" value="4.50" spread="5.25"/>
                    <measurement group_id="O3" value="2.10" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category G - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="2.49"/>
                    <measurement group_id="O2" value="-3.20" spread="4.71"/>
                    <measurement group_id="O3" value="-0.97" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category H- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="1.28"/>
                    <measurement group_id="O2" value="1.60" spread="2.27"/>
                    <measurement group_id="O3" value="1.70" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category H - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="1.20"/>
                    <measurement group_id="O2" value="0.20" spread="2.86"/>
                    <measurement group_id="O3" value="-0.67" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category I- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="1.92"/>
                    <measurement group_id="O2" value="3.20" spread="3.65"/>
                    <measurement group_id="O3" value="2.13" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category I - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.80"/>
                    <measurement group_id="O2" value="-1.30" spread="3.89"/>
                    <measurement group_id="O3" value="-0.93" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category J- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.99"/>
                    <measurement group_id="O2" value="0.40" spread="0.97"/>
                    <measurement group_id="O3" value="0.50" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category J - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.69"/>
                    <measurement group_id="O2" value="-0.30" spread="0.67"/>
                    <measurement group_id="O3" value="-0.23" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category K- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" spread="3.99"/>
                    <measurement group_id="O2" value="4.90" spread="2.85"/>
                    <measurement group_id="O3" value="4.23" spread="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category K - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.04" spread="2.90"/>
                    <measurement group_id="O2" value="-1.00" spread="3.50"/>
                    <measurement group_id="O3" value="-1.60" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category L- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="4.68"/>
                    <measurement group_id="O2" value="5.10" spread="5.00"/>
                    <measurement group_id="O3" value="6.03" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category L - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="3.46"/>
                    <measurement group_id="O2" value="-0.20" spread="6.03"/>
                    <measurement group_id="O3" value="-1.97" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category M- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="1.22"/>
                    <measurement group_id="O2" value="1.30" spread="2.06"/>
                    <measurement group_id="O3" value="0.50" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category M - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="1.08"/>
                    <measurement group_id="O2" value="-0.10" spread="3.21"/>
                    <measurement group_id="O3" value="0.30" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category N- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="1.54"/>
                    <measurement group_id="O2" value="2.20" spread="3.05"/>
                    <measurement group_id="O3" value="2.30" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category N - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="1.70"/>
                    <measurement group_id="O2" value="-0.90" spread="2.23"/>
                    <measurement group_id="O3" value="-0.80" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category O- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.71"/>
                    <measurement group_id="O2" value="0.30" spread="0.95"/>
                    <measurement group_id="O3" value="0.53" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category O - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.37"/>
                    <measurement group_id="O2" value="-0.20" spread="0.63"/>
                    <measurement group_id="O3" value="-0.13" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Child Symptom Inventory-4: Parent Checklist (CSI-4)</title>
        <description>The CSI-4 contains 97 items that screen for 15 emotional and behavioral disorders in children between 5 and 12 years old. Item score range:0 (no symptoms) to 3 (maximum impairment). Categories: A=ADHD (0-54); B=Conduct (0-60); C=Oppositional Defiant (0-24); D=Generalized Anxiety (0-18); E=Specific Phobia/Panic Attack/Obsessions/Compulsions/Somatization (0-30); F=Social Phobia (0-6); G=Separation Anxiety (0-24); H=Schizoid Personality (0-9); I=Schizophrenia (0-6); J=Enuresis (0-18).</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <population>Number of child patients with baseline and at least one nonmissing post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pure ADHD</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O2">
            <title>ADHD+Internalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O3">
            <title>ADHD+Externalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Child Symptom Inventory-4: Parent Checklist (CSI-4)</title>
          <description>The CSI-4 contains 97 items that screen for 15 emotional and behavioral disorders in children between 5 and 12 years old. Item score range:0 (no symptoms) to 3 (maximum impairment). Categories: A=ADHD (0-54); B=Conduct (0-60); C=Oppositional Defiant (0-24); D=Generalized Anxiety (0-18); E=Specific Phobia/Panic Attack/Obsessions/Compulsions/Somatization (0-30); F=Social Phobia (0-6); G=Separation Anxiety (0-24); H=Schizoid Personality (0-9); I=Schizophrenia (0-6); J=Enuresis (0-18).</description>
          <population>Number of child patients with baseline and at least one nonmissing post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Category A - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.00" spread="10.43"/>
                    <measurement group_id="O2" value="36.00" spread="9.32"/>
                    <measurement group_id="O3" value="38.95" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category A - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="9.76"/>
                    <measurement group_id="O2" value="-9.68" spread="9.54"/>
                    <measurement group_id="O3" value="-12.7" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category B - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.29" spread="4.72"/>
                    <measurement group_id="O2" value="11.05" spread="4.13"/>
                    <measurement group_id="O3" value="15.65" spread="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category B - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="3.88"/>
                    <measurement group_id="O2" value="-1.14" spread="5.25"/>
                    <measurement group_id="O3" value="-3.76" spread="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category C - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" spread="2.44"/>
                    <measurement group_id="O2" value="2.23" spread="2.25"/>
                    <measurement group_id="O3" value="4.63" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category C - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="2.11"/>
                    <measurement group_id="O2" value="-0.05" spread="3.06"/>
                    <measurement group_id="O3" value="-1.99" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category D - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" spread="3.37"/>
                    <measurement group_id="O2" value="8.23" spread="3.96"/>
                    <measurement group_id="O3" value="7.41" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category D - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="3.16"/>
                    <measurement group_id="O2" value="-2.23" spread="3.01"/>
                    <measurement group_id="O3" value="-1.63" spread="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category E - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="1.87"/>
                    <measurement group_id="O2" value="2.09" spread="1.95"/>
                    <measurement group_id="O3" value="2.79" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category E - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="1.90"/>
                    <measurement group_id="O2" value="-0.41" spread="1.74"/>
                    <measurement group_id="O3" value="-0.85" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category F - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.86"/>
                    <measurement group_id="O2" value="0.32" spread="0.57"/>
                    <measurement group_id="O3" value="0.91" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category F - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.94"/>
                    <measurement group_id="O2" value="-0.14" spread="0.64"/>
                    <measurement group_id="O3" value="-0.24" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category G - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" spread="2.70"/>
                    <measurement group_id="O2" value="4.05" spread="2.79"/>
                    <measurement group_id="O3" value="3.51" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category G - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="2.40"/>
                    <measurement group_id="O2" value="-0.91" spread="2.00"/>
                    <measurement group_id="O3" value="-0.46" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category H - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" spread="4.14"/>
                    <measurement group_id="O2" value="4.64" spread="4.02"/>
                    <measurement group_id="O3" value="4.45" spread="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category H - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="2.21"/>
                    <measurement group_id="O2" value="-1.09" spread="2.93"/>
                    <measurement group_id="O3" value="-1.54" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category I - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" spread="1.85"/>
                    <measurement group_id="O2" value="2.77" spread="1.38"/>
                    <measurement group_id="O3" value="2.94" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category I - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="1.83"/>
                    <measurement group_id="O2" value="-0.45" spread="1.47"/>
                    <measurement group_id="O3" value="-0.32" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category J - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" spread="3.98"/>
                    <measurement group_id="O2" value="5.58" spread="6.05"/>
                    <measurement group_id="O3" value="5.22" spread="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category J - Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="3.64"/>
                    <measurement group_id="O2" value="-0.86" spread="2.61"/>
                    <measurement group_id="O3" value="-1.55" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Conners' Teacher Rating Scale-Revised: Short Form (CTRS-R:S)</title>
        <description>A 28-item rating scale (0 [not at all/never] to 3 [very much true/very often]) completed by the teacher to assess problem behaviors related to ADHD. Subscale total scores range from 0 to 15 for Oppositional and Cognitive Problems, 0 to 21 for Hyperactivity, and 0 to 36 for ADHD Index.</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pure ADHD</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O2">
            <title>ADHD+Internalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
          <group group_id="O3">
            <title>ADHD+Externalizing Disorders</title>
            <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Conners' Teacher Rating Scale-Revised: Short Form (CTRS-R:S)</title>
          <description>A 28-item rating scale (0 [not at all/never] to 3 [very much true/very often]) completed by the teacher to assess problem behaviors related to ADHD. Subscale total scores range from 0 to 15 for Oppositional and Cognitive Problems, 0 to 21 for Hyperactivity, and 0 to 36 for ADHD Index.</description>
          <population>Number of patients with baseline and at least one nonmissing post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oppositional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" lower_limit="-2.22" upper_limit="-0.61"/>
                    <measurement group_id="O2" value="1.07" lower_limit="-0.33" upper_limit="2.46"/>
                    <measurement group_id="O3" value="-2.35" lower_limit="-3.55" upper_limit="-1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" lower_limit="-1.72" upper_limit="-0.45"/>
                    <measurement group_id="O2" value="-0.47" lower_limit="-1.74" upper_limit="0.80"/>
                    <measurement group_id="O3" value="-0.94" lower_limit="-1.77" upper_limit="-0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.87" lower_limit="-4.04" upper_limit="-1.69"/>
                    <measurement group_id="O2" value="-2.34" lower_limit="-4.80" upper_limit="0.11"/>
                    <measurement group_id="O3" value="-4.09" lower_limit="-5.52" upper_limit="-2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADHD Index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.94" lower_limit="-6.36" upper_limit="-3.52"/>
                    <measurement group_id="O2" value="-3.60" lower_limit="-6.65" upper_limit="-0.55"/>
                    <measurement group_id="O3" value="-6.62" lower_limit="-8.59" upper_limit="-4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pure ADHD</title>
          <description>Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
        </group>
        <group group_id="E2">
          <title>ADHD+Internalizing Disorders</title>
          <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
        </group>
        <group group_id="E3">
          <title>ADHD+Externalizing Disorders</title>
          <description>Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Idiosyncratic drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E3" events="32" subjects_affected="18" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" events="17" subjects_affected="12" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="97"/>
                <counts group_id="E2" events="19" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E3" events="36" subjects_affected="26" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="97"/>
                <counts group_id="E2" events="13" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" events="20" subjects_affected="15" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="97"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E3" events="39" subjects_affected="33" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="97"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E3" events="20" subjects_affected="14" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="34" subjects_affected="20" subjects_at_risk="97"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E3" events="35" subjects_affected="26" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="97"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E3" events="44" subjects_affected="34" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The original intent was to also calculate change and 95% confidence intervals at end of Period III; however, due to low number of patients completing Period III, variations from baseline (LOCF), are not suitable for further analysis or description.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

